Get the Stockscreener App
7.59
2.57%
-0.20
After Hours:
7.59
Arvinas Inc stock is traded at $7.59, with a volume of 713.34K.
It is down -2.57% in the last 24 hours and down -20.94% over the past month.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
See More
Previous Close:
$7.79
Open:
$7.78
24h Volume:
713.34K
Relative Volume:
0.88
Market Cap:
$496.28M
Revenue:
$89.40M
Net Income/Loss:
$-221.30M
P/E Ratio:
-2.3308
EPS:
-3.2564
Net Cash Flow:
$-256.90M
1W Performance:
-8.44%
1M Performance:
-20.94%
6M Performance:
-30.49%
1Y Performance:
-2.06%
1-Day Range:
$7.535
$7.81
1-Week Range:
$7.39
$8.64
52-Week Range:
$6.97
$14.51
Arvinas Inc Stock (ARVN) Company Profile
Name
Arvinas Inc
Sector
Industry
Phone
203-535-1456
Address
395 WINCHESTER AVE, NEW HAVEN, CT
Compare ARVN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
7.59 | 496.28M | 89.40M | -221.30M | -256.90M | -3.2564 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Oct-15-25 | Downgrade | Goldman | Neutral → Sell |
| Sep-24-25 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-17-25 | Resumed | Barclays | Overweight |
| Jun-02-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-05-25 | Downgrade | Truist | Buy → Hold |
| May-02-25 | Downgrade | Jefferies | Buy → Hold |
| May-02-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-13-25 | Downgrade | Goldman | Buy → Neutral |
| Mar-12-25 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-11-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-10-24 | Initiated | BTIG Research | Buy |
| Nov-18-24 | Initiated | Stephens | Overweight |
| Feb-28-24 | Reiterated | Oppenheimer | Outperform |
| Feb-14-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-01-24 | Initiated | Goldman | Buy |
| Dec-19-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-06-23 | Upgrade | Jefferies | Hold → Buy |
| Nov-20-23 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-23-23 | Upgrade | Wedbush | Neutral → Outperform |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Jan-12-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jan-03-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-22 | Initiated | Barclays | Overweight |
| Jun-21-22 | Initiated | Jefferies | Hold |
| May-09-22 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-28-22 | Initiated | Credit Suisse | Outperform |
| Apr-06-22 | Initiated | Morgan Stanley | Equal-Weight |
| Feb-11-22 | Resumed | BMO Capital Markets | Outperform |
| Feb-10-22 | Initiated | Wells Fargo | Overweight |
| Jan-19-22 | Initiated | Goldman | Buy |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Oct-14-21 | Initiated | SVB Leerink | Outperform |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-09-21 | Initiated | BofA Securities | Buy |
| May-21-21 | Initiated | UBS | Buy |
| Apr-21-21 | Initiated | Truist | Buy |
| Mar-31-21 | Initiated | BMO Capital Markets | Outperform |
| Dec-14-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Jun-01-20 | Upgrade | Citigroup | Neutral → Buy |
| May-12-20 | Initiated | Oppenheimer | Perform |
| Dec-19-19 | Initiated | H.C. Wainwright | Buy |
| Nov-25-19 | Initiated | Guggenheim | Buy |
| Oct-24-19 | Upgrade | Goldman | Neutral → Buy |
| Sep-25-19 | Initiated | Wedbush | Outperform |
| Sep-12-19 | Initiated | BMO Capital Markets | Outperform |
| Aug-06-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-05-19 | Downgrade | Citigroup | Buy → Neutral |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Oct-22-18 | Initiated | Citigroup | Buy |
| Oct-22-18 | Initiated | Goldman | Neutral |
| Oct-22-18 | Initiated | Piper Jaffray | Overweight |
View All
Arvinas Inc Stock (ARVN) Latest News
Form 144 ARVINAS For: 27 September By Investing.com - Investing.com Australia
Arvinas Q2 2026 Earnings Call Transcript - benzinga.com
Arvinas (NASDAQ: ARVN) director plans stock sale under SEC resale rule - Stock Titan
ARVN Q2 2026 Earnings: EPS Swings to $2.58, Beating Estimates by a Wide MarginEarnings Outlook Update - dars.gov.et
Arvinas, Inc. (ARVN) Stock Analysis: Uncovering a Potential 67.61% Upside in the Biotech Sector - DirectorsTalk Interviews
Arvinas, Inc. $ARVN Shares Purchased by Squarepoint Ops LLC - MarketBeat
Piper Sandler Maintains Arvinas(ARVN.US) With Buy Rating, Maintains Target Price $20 - Moomoo
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Arvinas at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline takes center stage - investing.com
ARVN Stock Jumps 10% After FDA Approves Breast Cancer Drug A Month Ahead Of Schedule - Stocktwits
Former Arvinas (NASDAQ: ARVN) officer plans new stock sale - Stock Titan
(ARVN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Arvinas (ARVN) Just Made Protein Degrader History With FDA Nod - Yahoo Finance
Arvinas at Wells Fargo conference: pipeline nears key data By Investing.com - Investing.com South Africa
Arvinas (ARVN) Stock Price, News & Analysis - Stock Titan
ARVN News | ARVINAS INC (NASDAQ:ARVN) - ChartMill
Former Arvinas (NASDAQ: ARVN) officer lines up new stock sale after recent trades - Stock Titan
ARVN Stock Drops On CEO Exit — Retail Is Bullish On New Chief’s Credentials, Dismisses Selloff - Stocktwits
Arvinas to Participate in Upcoming Investor Conferences - Yahoo Finance
Arvinas Inc. (ARVN) Key Financial Ratios – Valuation, Profitability & More - Value Research
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Arvinas Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4) - TradingView
Arvinas Inc. (ARVN) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ARVN Q2 2026 Earnings: EPS of $2.58 Blows Past Consensus; Stock Slips 0.65%Tax Rate Impact - vinanet.vn
The Technical Signals Behind (ARVN) That Institutions Follow - Stock Traders Daily
Arvinas: Veppanu Approval Underlines Degrader Platform PromiseI'm Bullish (NASDAQ:ARVN) - Seeking Alpha
Arvinas (ARVN) Momentum: Gains 3.77% to Reach $9.37 in the Current Update; Chart Watch - dars.gov.et
Arvinas (ARVN) Quarterly Results: EPS Lands Above Forecast for the Current Session; Trading Response: Shares Finish 4.54% Higher at the ClosePerformance Review - vinanet.vn
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Arvinas (ARVN) Q2 2026 Filing Snapshot: Reported EPS Tops Expectations at the Close; Price Reaction: Shares Move 0.22% Up in the Current UpdateEPS Growth Report - dars.gov.et
142,214 Shares in Arvinas, Inc. $ARVN Purchased by GSA Capital Partners LLP - MarketBeat
Arvinas Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
Arvinas (ARVN) Holds Ground Near $8.97 as Biotech Stock Tests Key Support ZoneConversion Trade - vinanet.vn
Arvinas Inc (ARVN) Stock Price, Quote, News & History - Benzinga
D. E. Shaw adjusts Arvinas (ARVN) stake as one entity falls below 5% - Stock Titan
Arvinas (ARVN) Q2 2026 Earnings Call Transcript - AOL.com
Morgan Stanley Maintains Arvinas(ARVN.US) With Hold Rating, Maintains Target Price $10 - Moomoo
Enterprise value to EBITDA forward of Arvinas, Inc. – NASDAQ:ARVN - tradingview.com
ARVN Maintains by Evercore ISI Group -- Price Target Lowered to $14.00 - GuruFocus
ARVN Maintained by Citigroup -- Price Target Lowered to $21.00 - GuruFocus
A Quick Look at Today's Ratings for Arvinas(ARVN.US), With a Forecast Between $10 to $21 - Moomoo
Arvinas, Inc. Stock 12‑Month Price Target Cut to $13.93, Implies 59% Upside - TradingView
Morgan Stanley Adjusts Price Target on Arvinas to $10 From $11, Maintains Equalweight Rating - Yahoo Finance
Precision Trading with Arvinas Inc. (ARVN) Risk Zones - Stock Traders Daily
Analysts Offer Insights on Healthcare Companies: Arvinas Holding Company (ARVN), 10x Genomics (TXG) and Teleflex (TFX) - The Globe and Mail
Arvinas (NASDAQ:ARVN) Rating Increased to Hold at Wall Street Zen - MarketBeat
Arvinas Inc (ARVN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BofA Securities Maintains Arvinas(ARVN.US) With Hold Rating - Moomoo
Enterprise value to EBIT forward of Arvinas, Inc. – NASDAQ:ARVN - TradingView
Arvinas (NASDAQ:ARVN) Upgraded to "Strong-Buy" at Zacks Research - marketbeat.com
Arvinas, Inc. (ARVN) stock price, news, quote and history - Yahoo Finance Australia
Arvinas Inc Stock (ARVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):